ANZCTR search results

1. This study will examine the use and safety of FB and BAL to identify lower respiratory tract infection (especially PA) in infants and young children with CF and direct therapy in an attempt to eradicate proven early lung infection. 2. The role of infection and inflammation in the development of CF lung disease will be examined in a large cohort of CF infants recruited prospectively and followed longitudinally.

This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.

A prospective, non-randomised, 48 week study of the effect of PI containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular structure in HIV-infected individuals, naive to therapy, who are starting therapy for the first time.

A randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects

Saquinavir and Atazanavir are drugs used in combination therapy to treat HIV disease. Saquinavir is currently available in a 200 milligram capsule. Most individuals currently on saquinavir require to take 5 tablets twice a day. In an attempt to reduce this number of pills, a new capsule has been developed containing 500 milligrams of saquinavir. This study will assess: i) blood drug levels in individuals taking both saquinavir formulations, ii) blood drug levels in individuals taking both saquinavir formulations when given with atazanavir, iii) 48 weeks of follow up for individuals receiving the new saquinavir formulation with atazanavir as HIV therapy.

This project will systematically apply a specialist version of Cognitive Behaviour Therapy (CBT), known as Recovery Therapy, to a random sample of patients with psychotic disorders. Previously, the therapy has been developed and efficacy established, but the extent of applicability to (unselected) mental health service patients is unknown. The main aim is to establish the extent to which this therapy is acceptable and effective for mental health service clients. A secondary aim is to develop guidelines for the conduct of such therapy in public mental health settings.

The study hypothesis is that an annual high dose (500,000 IU) of vitamin D2 will reduce the rate of falls and fracture compared with placebo in older women.

Patients taking beta interferon therapy for multiple sclerosis may develop antibodies to the therapy, called neutralising antibodies. These antibodies can block the action of interferon, reducing its bio-availability for use in the body, thereby reducing its effectiveness as a treatment. This study explores one possible way of reducing the levels of neutralising antibodies in the system by suspending interferon treatment, treating the patient with methylprednisolone to reduce the antibody levels, then restarting interferon therapy by giving AVONEX injections once weekly, and testing to see if the bio-availability or 'effectiveness' of the interferon therapy is restored.

This project is a trial of amisulpride in the treatment of schizophrenia and schizoaffective disorder over a 24-week period. Atypical antipsychotic medications, such as amisulpride, are being used more and more to treat the debilitating effects of psychotic symptoms. The trial will be conducted over a 24-week period. It is expected that 40 patients will be recruited to this project. During the 24 weeks, parameters such as tolerability and safety will be assessed using a number of well validated Extra-Pyramidal Side Effects scales in addition to regular monitoring of vital signs, lab, and ECG results. Efficacy assessments will include the PANSS, CGI scales and an appropriate quality of life scale. Patients will also be administered a battery of neuropsychological tests at baseline and 24 weeks to assess and monitor change in cognitive function. Data will be processed using standard statistical techniques.